| US4000259A (en) | 1975-06-16 | 1976-12-28 | American Home Products Corporation | Cyclic dodecapeptide analogs of somatostatin and intermediates |
| US4438270A (en) | 1977-07-11 | 1984-03-20 | Merrell Toraude Et Compagnie | α-Halomethyl derivatives of α-amino acids |
| US4191754A (en) | 1979-02-28 | 1980-03-04 | Merck & Co., Inc. | Bicyclic somatostatin analogs |
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| AU550730B2 (en) | 1982-03-09 | 1986-04-10 | Commonwealth Of Australia, The | Automated metal detection |
| US4728726A (en) | 1982-10-04 | 1988-03-01 | The Salk Institute For Biological Studies | GRF analogs IIIb |
| US4518586A (en) | 1983-01-13 | 1985-05-21 | The Salk Institute For Biological Studies | GRF Analogs III |
| US5416073A (en) | 1983-08-10 | 1995-05-16 | The Adminstrators Of The Tulane Educational Fund | Growth hormone-releasing peptides and method of treating animals, therewith |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5036045A (en) | 1985-09-12 | 1991-07-30 | The University Of Virginia Alumni Patents Foundation | Method for increasing growth hormone secretion |
| US4730006A (en) | 1986-01-27 | 1988-03-08 | Merrell Dow Pharmaceuticals Inc. | Derivatives of 2,6-diamino-3-haloheptanedioic acid |
| US4880778A (en) | 1986-05-12 | 1989-11-14 | Eastman Kodak Company | Combinations having synergistic growth hormone releasing activity and methods for use thereof |
| HU906341D0 (en) | 1986-10-13 | 1991-04-29 | Sandoz Ag | Process for producing peptonic derivatives modified with sugar and pharmaceutical preparatives containing these compounds as active substance |
| US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| US5112808A (en) | 1987-05-11 | 1992-05-12 | American Cyanamid Company | Alkylated hormone-releasing peptides and method of treatig mammals therewith |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5877277A (en) | 1987-09-24 | 1999-03-02 | Biomeasure, Inc. | Octapeptide bombesin analogs |
| US5453418A (en) | 1988-03-07 | 1995-09-26 | Eli Lilly And Company | Ractopamine and growth hormone combinations |
| US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
| AU3439589A (en) | 1988-03-24 | 1989-10-16 | Terrapin Diagnostics, Inc. | Molecular sticks for controlling protein conformation |
| US5094951A (en) | 1988-06-21 | 1992-03-10 | Chiron Corporation | Production of glucose oxidase in recombinant systems |
| US5043322A (en) | 1988-07-22 | 1991-08-27 | The Salk Institute For Biological Studies | Cyclic GRF analogs |
| FR2638359A1 (en) | 1988-11-03 | 1990-05-04 | Tino Dalto | SYRINGE GUIDE WITH ADJUSTMENT OF DEPTH DEPTH OF NEEDLE IN SKIN |
| US5384309A (en) | 1989-07-17 | 1995-01-24 | Genentech, Inc. | Cyclized peptides and their use as platelet aggregation inhibitors |
| US5120859A (en) | 1989-09-22 | 1992-06-09 | Genentech, Inc. | Chimeric amino acid analogues |
| US5712418A (en) | 1989-10-23 | 1998-01-27 | Research Corporation Technologies, Inc. | Synthesis and use of amino acid fluorides as peptide coupling reagents |
| US5650133A (en) | 1990-01-19 | 1997-07-22 | Nycomed Salutar | Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality |
| US5169932A (en) | 1989-10-30 | 1992-12-08 | The Salk Institute For Biological Studies | Gnrh analogs |
| US5352796A (en) | 1989-10-30 | 1994-10-04 | The Salk Institute For Biological Studies | Amino acids useful in making GnRH analogs |
| US5296468A (en) | 1989-10-30 | 1994-03-22 | The Salk Institute For Biological Studies | GnRH analogs |
| US5580957A (en) | 1989-10-30 | 1996-12-03 | The Salk Institute For Biological Studies | GnRH analogs |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5245009A (en) | 1990-03-23 | 1993-09-14 | The Salk Institute For Biological Studies | CRF antagonists |
| CA2047042A1 (en) | 1990-07-19 | 1992-01-20 | John Hannah | Cyclic hiv principal neutralizing determinant peptides |
| US5629020A (en) | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
| US5714167A (en) | 1992-06-15 | 1998-02-03 | Emisphere Technologies, Inc. | Active agent transport systems |
| US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| PL168456B1 (en) | 1990-10-11 | 1996-02-29 | Boehringer Ingelheim Kg | Method for producing PL PL PL cyclopeptides |
| EP0488258B1 (en) | 1990-11-27 | 1996-04-17 | Fuji Photo Film Co., Ltd. | Propenamide derivatives, polymers, copolymers and use thereof |
| US5124454A (en) | 1990-11-30 | 1992-06-23 | Minnesota Mining And Manufacturing Company | Polycyclic diamines and method of preparation |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| WO1992013878A2 (en) | 1991-02-07 | 1992-08-20 | Board Of Trustees Of The University Of Illinois | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same |
| US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| US5744450A (en) | 1991-03-14 | 1998-04-28 | The Salk Institute For Biological Studies | GnRH analogs |
| EP0525838A3 (en) | 1991-04-09 | 1993-02-10 | F. Hoffmann-La Roche Ag | Growth hormone releasing factor analogs |
| US5262519A (en) | 1991-05-15 | 1993-11-16 | The Salk Institute For Biological Studies | GRF analogs XI |
| US5364851A (en) | 1991-06-14 | 1994-11-15 | International Synthecon, Llc | Conformationally restricted biologically active peptides, methods for their production and uses thereof |
| CA2072249C (en) | 1991-06-28 | 2003-06-17 | Saiko Hosokawa | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane |
| GB9114949D0 (en) | 1991-07-11 | 1991-08-28 | Smithkline Beecham Plc | Novel compounds |
| EP0528312B1 (en) | 1991-08-13 | 1997-07-16 | Takeda Chemical Industries, Ltd. | Cyclic peptides and use thereof |
| GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
| US7517644B1 (en) | 1991-08-23 | 2009-04-14 | Larry J. Smith | Method and compositions for cellular reprogramming |
| SE9102652D0 (en) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | INJECTION NEEDLE ARRANGEMENT |
| IL103252A (en) | 1991-09-30 | 1997-03-18 | Du Pont Merck Pharma | CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| ES2133295T3 (en) | 1991-11-19 | 1999-09-16 | Takeda Chemical Industries Ltd | CYCLIC PEPTIDES AND THEIR USE. |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| EP0773948A4 (en) | 1992-04-03 | 1998-09-02 | California Inst Of Techn | HIGHLY ACTIVE RUTHENIUM OR OSMIUM METAL CARBEN COMPLEXES FOR OLEFIN METHETHESE REACTIONS AND THEIR SYNTHESIS |
| US5411860A (en) | 1992-04-07 | 1995-05-02 | The Johns Hopkins University | Amplification of human MDM2 gene in human tumors |
| AU681853B2 (en) | 1992-05-26 | 1997-09-11 | Rijksuniversiteit Leiden | Peptides of human p53 protein for use in human T cell response inducing compositions, and human p53 protein-specific cytotoxic T-lymphocytes |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| EP0651761B1 (en) | 1992-07-13 | 2002-10-09 | Bionebraska, Inc. | Method for modification of recombinant polypeptides |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
| US5371070A (en) | 1992-11-09 | 1994-12-06 | The Salk Institute For Biological Studies | Bicyclic GnRH antagonists and a method for regulating the secretion of gonadotropins |
| ATE167396T1 (en) | 1993-02-22 | 1998-07-15 | Alza Corp | AGENTS FOR THE ORAL ADMINISTRATION OF ACTIVE INGREDIENTS |
| HUT72896A (en) | 1993-03-29 | 1996-06-28 | Du Pont Merck Pharma | Cyclic compounds useful as inhibitors of platelet glycoprotein iib/iiia |
| US5643957A (en) | 1993-04-22 | 1997-07-01 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| WO1994025482A1 (en) | 1993-04-23 | 1994-11-10 | Evans Herbert J | Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site |
| US5446128A (en) | 1993-06-18 | 1995-08-29 | The Board Of Trustees Of The University Of Illinois | Alpha-helix mimetics and methods relating thereto |
| ES2196031T3 (en) | 1993-08-09 | 2003-12-16 | Sod Conseils Rech Applic | PEPTIDIC THERAPEUTIC DERIVATIVES. |
| US5622852A (en) | 1994-10-31 | 1997-04-22 | Washington University | Bcl-x/Bcl-2 associated cell death regulator |
| US5536814A (en) | 1993-09-27 | 1996-07-16 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
| JPH09505735A (en) | 1993-11-22 | 1997-06-10 | オニックス ファーマシューティカルズ，インコーポレイティド | p53-binding polypeptides and polynucleotides encoding same |
| US6287787B1 (en) | 1993-11-24 | 2001-09-11 | Torrey Pines Institute For Molecular Studies | Dimeric oligopeptide mixture sets |
| AU1967495A (en) | 1994-02-18 | 1995-09-04 | Cell Therapeutics, Inc. | Intracellular signalling mediators |
| WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
| US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
| US5506207A (en) | 1994-03-18 | 1996-04-09 | The Salk Institute For Biological Studies | GNRH antagonists XIII |
| US5824483A (en) | 1994-05-18 | 1998-10-20 | Pence Inc. | Conformationally-restricted combinatiorial library composition and method |
| JP3166482B2 (en) | 1994-06-07 | 2001-05-14 | 日産自動車株式会社 | Coloring structure having reflective interference action |
| IL109943A (en) | 1994-06-08 | 2006-08-01 | Develogen Israel Ltd | Conformationally constrained backbone cyclized peptide analogs |
| US6407059B1 (en) | 1994-06-08 | 2002-06-18 | Peptor Limited | Conformationally constrained backbone cyclized peptide analogs |
| US7553929B2 (en) | 1994-06-13 | 2009-06-30 | Vanderbilt University | Cell permeable peptides for inhibition of inflammatory reactions and methods of use |
| US5807746A (en) | 1994-06-13 | 1998-09-15 | Vanderbilt University | Method for importing biologically active molecules into cells |
| US5770377A (en) | 1994-07-20 | 1998-06-23 | University Of Dundee | Interruption of binding of MDM2 and P53 protein and therapeutic application thereof |
| US5702908A (en) | 1994-07-20 | 1997-12-30 | University Of Dundee | Interruption of binding of MDM2 and p53 protein and therapeutic application thereof |
| CN1132012C (en) | 1994-09-19 | 2003-12-24 | 里卡尔多·J·莫罗 | Cancer Detection and Treatment |
| CA2158782C (en) | 1994-09-23 | 2010-01-12 | Pierrette Gaudreau | Marker for growth hormone-releasing factor receptors |
| US5681928A (en) | 1994-12-16 | 1997-10-28 | The Salk Institute For Biological Studies | Betides and methods for screening peptides using same |
| CA2209183A1 (en) | 1994-12-29 | 1996-07-11 | Joel L. Pomerantz | Chimeric dna-binding proteins |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| US5792747A (en) | 1995-01-24 | 1998-08-11 | The Administrators Of The Tulane Educational Fund | Highly potent agonists of growth hormone releasing hormone |
| US6169073B1 (en) | 1995-02-16 | 2001-01-02 | Bayer Corporation | Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function |
| EP0729972A1 (en) | 1995-02-28 | 1996-09-04 | F. Hoffmann-La Roche Ag | Peptide derivatives of tetrahydronaphthalene |
| US6514942B1 (en) | 1995-03-14 | 2003-02-04 | The Board Of Regents, The University Of Texas System | Methods and compositions for stimulating T-lymphocytes |
| US5675001A (en) | 1995-03-14 | 1997-10-07 | Hoffman/Barrett, L.L.C. | Heteroatom-functionalized porphyrazines and multimetallic complexes and polymers derived therefrom |
| US5700775A (en) | 1995-03-24 | 1997-12-23 | Gutniak; Mark K. | Method and treatment composition for decreasing patient time in catabolic state after traumatic injury |
| CN1151836C (en) | 1995-03-31 | 2004-06-02 | 艾米斯菲尔技术有限公司 | Compound and compositions for delivering active agents |
| US6090958A (en) | 1995-03-31 | 2000-07-18 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| US6054556A (en) | 1995-04-10 | 2000-04-25 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Melanocortin receptor antagonists and agonists |
| US5731408A (en) | 1995-04-10 | 1998-03-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Peptides having potent antagonist and agonist bioactivities at melanocortin receptors |
| EP0820296A4 (en) | 1995-04-14 | 1999-06-30 | Univ Tulane | Analogs of growth hormone-releasing factor |
| US5672584A (en) | 1995-04-25 | 1997-09-30 | The University Of Kansas | Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability |
| US6184344B1 (en) | 1995-05-04 | 2001-02-06 | The Scripps Research Institute | Synthesis of proteins by native chemical ligation |
| PT832096E (en) | 1995-05-04 | 2002-01-30 | Scripps Research Inst | SYNTHESIS OF PROTEINS THROUGH NATIVE CHEMICAL LIGACATION |
| US6020311A (en) | 1995-05-26 | 2000-02-01 | Theratechnologies, Inc. | GRF analogs with increased biological potency |
| CA2222068C (en) | 1995-05-26 | 2007-04-10 | Theratechnologies Inc. | Chimeric fatty body-pro-grf analogs with increased biological potency |
| US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
| US6458764B1 (en) | 1995-05-26 | 2002-10-01 | Theratechnologies Inc. | GRF analogs with increased biological potency |
| US5817789A (en) | 1995-06-06 | 1998-10-06 | Transkaryotic Therapies, Inc. | Chimeric proteins for use in transport of a selected substance into cells |
| US6413994B1 (en) | 1999-02-22 | 2002-07-02 | The Salk Institute For Biological Studies | Modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof |
| US6051554A (en) | 1995-06-07 | 2000-04-18 | Peptor Limited | Conformationally constrained backbone cyclized somatostatin analogs |
| US5811515A (en) | 1995-06-12 | 1998-09-22 | California Institute Of Technology | Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis |
| FR2738151B1 (en) | 1995-09-04 | 1997-09-26 | Rhone Poulenc Rorer Sa | ANTAGONISTS OF THE ONCOGENIC ACTIVITY OF THE MDM2 PROTEIN, AND THEIR USE IN THE TREATMENT OF CANCERS |
| EP0766966A3 (en) | 1995-09-08 | 2001-02-28 | Eli Lilly And Company | Method of treating insulin resistance |
| US5750499A (en) | 1995-10-18 | 1998-05-12 | The Salk Institute For Biological Studies | Receptor-selective somatostatin analogs |
| GB9521544D0 (en) | 1995-10-20 | 1995-12-20 | Univ Dundee | Activation of P53 protein and therapeutic applications thereof |
| US6123964A (en) | 1995-10-27 | 2000-09-26 | Merck & Co., Inc. | Wet granulation formulation of a growth hormone secretagogue |
| US5840833A (en) | 1995-10-27 | 1998-11-24 | Molecumetics, Ltd | Alpha-helix mimetics and methods relating thereto |
| CA2239711A1 (en) | 1995-12-22 | 1997-07-03 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| US5807983A (en) | 1995-12-28 | 1998-09-15 | The Salk Institute For Biological Studies | GNRH antagonist betides |
| US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
| WO1997026002A1 (en) | 1996-01-17 | 1997-07-24 | California Institute Of Technology | Synthesis of conformationally restricted amino acids, peptides and peptidomimetics by catalytic ring closing metathesis |
| US5849954A (en) | 1996-01-18 | 1998-12-15 | Research Corporation Technologies, Inc. | Method of peptide synthesis |
| US5849691A (en) | 1996-02-20 | 1998-12-15 | The United States Of America As Represented By The Department Of Health And Human Services | Peptidomimetic inhibitors of cathepsin D and plasmepsins I and II |
| IL126318A (en) | 1996-03-29 | 2004-09-27 | Emisphere Tech Inc | Compounds and compositions for delivering active agents and some novel carrier compounds |
| GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
| JP3792777B2 (en)* | 1996-05-10 | 2006-07-05 | 株式会社カネカ | Method for producing 1-alkoxycarbonyl-3-phenylpropyl derivative |
| AU3220097A (en) | 1996-05-22 | 1997-12-09 | Arch Development Corporation | Sleep quality improvement using a growth hormone secretagogue |
| US5817752A (en) | 1996-06-06 | 1998-10-06 | La Jolla Pharmaceutical Company | Cyclic polypeptides comprising a thioether linkage and methods for their preparation |
| US5817627A (en) | 1996-06-14 | 1998-10-06 | Theratechnologies Inc. | Long-acting galenical formulation for GRF peptides |
| ATE185146T1 (en) | 1996-06-14 | 1999-10-15 | Takeda Chemical Industries Ltd | METHOD FOR REMOVAL OF N-TERMINAL METHIONINE |
| US5663316A (en) | 1996-06-18 | 1997-09-02 | Clontech Laboratories, Inc. | BBC6 gene for regulation of cell death |
| US7083983B2 (en) | 1996-07-05 | 2006-08-01 | Cancer Research Campaign Technology Limited | Inhibitors of the interaction between P53 and MDM2 |
| WO1998001467A2 (en) | 1996-07-05 | 1998-01-15 | Novartis Ag | Inhibitors of the interaction between p53 and mdm2 |
| JP4425992B2 (en) | 1996-07-22 | 2010-03-03 | サファイア セラピューティクス，インコーポレイティド | Compounds with growth hormone releasing properties |
| US5955593A (en) | 1996-09-09 | 1999-09-21 | Washington University | BH3 interacting domain death agonist |
| US20020064546A1 (en) | 1996-09-13 | 2002-05-30 | J. Milton Harris | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
| US5965703A (en) | 1996-09-20 | 1999-10-12 | Idun Pharmaceuticals | Human bad polypeptides, encoding nucleic acids and methods of use |
| GB9619757D0 (en) | 1996-09-21 | 1996-11-06 | Knoll Ag | Chemical process |
| US5856445A (en) | 1996-10-18 | 1999-01-05 | Washington University | Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator |
| AU4722197A (en) | 1996-10-22 | 1998-05-15 | Daiichi Pharmaceutical Co., Ltd. | Novel remedies for infectious diseases |
| US6271198B1 (en) | 1996-11-06 | 2001-08-07 | Genentech, Inc. | Constrained helical peptides and methods of making same |
| JP2001504831A (en) | 1996-11-21 | 2001-04-10 | プロメガ・コーポレーション | Alkyl peptide amides and applications |
| US6313088B1 (en) | 1997-02-07 | 2001-11-06 | Emisphere Technologies, Inc. | 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents |
| US6060513A (en) | 1997-02-07 | 2000-05-09 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| CZ290347B6 (en) | 1997-02-07 | 2002-07-17 | Ústav organické chemie a biochemie AV ČR | Cyclopeptides stimulating growth hormone release and process of their preparation |
| CA2281204A1 (en) | 1997-02-20 | 1998-08-27 | Yeda Research And Development Co., Ltd. | Antipathogenic synthetic peptides and compositions comprising them |
| US6849428B1 (en) | 1997-03-05 | 2005-02-01 | New England Biolabs, Inc. | Intein-mediated protein ligation of expressed proteins |
| US6635740B1 (en) | 1997-03-27 | 2003-10-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Ligand/lytic peptide compositions and methods of use |
| EP1015479A4 (en) | 1997-04-11 | 2002-07-24 | Lilly Co Eli | Combinatorial libraries of peptidomimetic macrocycles and processes therefor |
| GB9708092D0 (en) | 1997-04-22 | 1997-06-11 | Univ Dundee | Materials and methods relating to inhibiting the interaction of p53 and mdm2 |
| US6329368B1 (en) | 1997-05-09 | 2001-12-11 | The Regents Of The University Of California | Endocrine modulation with positive modulators of AMPA type glutamate receptors |
| CA2289960A1 (en) | 1997-05-15 | 1998-11-19 | Kyowa Hakko Kogyo Co., Ltd. | Peptides having a cyclic structure and restoring the activities of p53 protein to mutant p53 protein |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| US6127341A (en) | 1997-06-20 | 2000-10-03 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| US6248358B1 (en) | 1998-08-25 | 2001-06-19 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets and methods of making and using the same |
| EP1015578A4 (en) | 1997-09-17 | 2004-12-01 | Walker And Eliza Hall Inst Of | THERAPEUTIC MOLECULES |
| WO1999016790A1 (en) | 1997-09-26 | 1999-04-08 | University Technologies International, Inc. | Use of the tumour suppressor gene p33ing1 for modulation of p53 activity and in tumour diagnosis |
| US6165732A (en) | 1997-10-14 | 2000-12-26 | Washington University | Method for identifying apoptosis modulating compounds |
| US6875594B2 (en) | 1997-11-13 | 2005-04-05 | The Rockefeller University | Methods of ligating expressed proteins |
| US6177076B1 (en) | 1997-12-09 | 2001-01-23 | Thomas Jefferson University | Method of treating bladder cancer with wild type vaccinia virus |
| EP1053019B1 (en) | 1998-01-07 | 2003-12-03 | Debio Recherche Pharmaceutique S.A. | Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom |
| IT1298087B1 (en) | 1998-01-08 | 1999-12-20 | Fiderm S R L | DEVICE FOR CHECKING THE PENETRATION DEPTH OF A NEEDLE, IN PARTICULAR APPLICABLE TO A SYRINGE FOR INJECTIONS |
| US6030997A (en) | 1998-01-21 | 2000-02-29 | Eilat; Eran | Acid labile prodrugs |
| AU2329199A (en) | 1998-01-29 | 1999-08-16 | Poly-Med, Inc. | Absorbable microparticles |
| ATE240121T1 (en) | 1998-01-29 | 2003-05-15 | Kinerton Ltd | METHOD FOR PRODUCING ABSORBABLE MICROPARTICLES |
| NZ506839A (en) | 1998-03-09 | 2003-05-30 | Zealand Pharma As | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| AU767185B2 (en) | 1998-03-23 | 2003-11-06 | President And Fellows Of Harvard College | Synthesis of compounds and libraries of compounds |
| CZ20003798A3 (en) | 1998-04-15 | 2001-08-15 | Aventis Pharmaceuticals Products, Inc. | Process for preparing cyclic peptides attached to polymer carrier |
| US6190699B1 (en) | 1998-05-08 | 2001-02-20 | Nzl Corporation | Method of incorporating proteins or peptides into a matrix and administration thereof through mucosa |
| AU4543899A (en) | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
| US6326354B1 (en) | 1998-08-19 | 2001-12-04 | Washington University | Modulation of apoptosis with bid |
| US6194402B1 (en) | 1998-09-02 | 2001-02-27 | Merck & Co., Inc. | Enhancement of return to independent living status with a growth hormone secretagogue |
| US7173005B2 (en) | 1998-09-02 | 2007-02-06 | Antyra Inc. | Insulin and IGF-1 receptor agonists and antagonists |
| US6572856B1 (en) | 1998-09-10 | 2003-06-03 | The University Of Virginia Patent Foundation | Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies |
| US6696063B1 (en) | 1998-12-30 | 2004-02-24 | Applied Research Systems Ars Holding N.V. | Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy |
| CA2360671A1 (en) | 1999-01-29 | 2000-08-03 | The Board Of Trustees Of The University Of Illinois | P53 inhibitors and therapeutic use of the same |
| US6372490B1 (en) | 1999-02-23 | 2002-04-16 | Curagen Corporation | Nucleic acid encoding the MDM interacting protein |
| EP1216309A2 (en) | 1999-03-01 | 2002-06-26 | Variagenics, Inc. | Methods for targeting rna molecules |
| AU763510B2 (en) | 1999-03-29 | 2003-07-24 | Procter & Gamble Company, The | Melanocortin receptor ligands |
| US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| US6713280B1 (en) | 1999-04-07 | 2004-03-30 | Thomas Jefferson University | Enhancement of peptide cellular uptake |
| WO2000064283A1 (en) | 1999-04-27 | 2000-11-02 | International Health Products And Services Ltd. | Supplement for restoring growth hormone levels |
| US20090175821A1 (en) | 1999-05-17 | 2009-07-09 | Bridon Dominique P | Modified therapeutic peptides with extended half-lives in vivo |
| JP4217004B2 (en) | 1999-05-17 | 2009-01-28 | コンジュケム バイオテクノロジーズ インコーポレイテッド | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
| WO2000071096A2 (en) | 1999-05-24 | 2000-11-30 | Introgen Therapeutics, Inc. | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases |
| MXPA02000938A (en) | 1999-07-26 | 2004-03-19 | Baylor College Medicine | Super active porcine growth hormone releasing hormone analog. |
| US6461634B1 (en) | 1999-08-20 | 2002-10-08 | Edward Marshall | Food-based delivery of HGH-stimulating and other nutritional supplements |
| US20080032931A1 (en) | 1999-08-25 | 2008-02-07 | Steward Lance E | Activatable clostridial toxins |
| US6696418B1 (en) | 1999-09-01 | 2004-02-24 | Pfizer Inc. | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor |
| US20020016298A1 (en) | 1999-09-01 | 2002-02-07 | Hay Bruce A. | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor |
| US20030181367A1 (en) | 1999-09-27 | 2003-09-25 | O'mahony Daniel | Conjugates of membrane translocating agents and pharmaceutically active agents |
| DE60042527D1 (en) | 1999-11-22 | 2009-08-20 | Zymogenetics Inc | METHOD FOR FORMING A PEPTIDE RECEPTOR COMPLEX WITH ZSIG33 POLYPEPTIDES. |
| US6831155B2 (en) | 1999-12-08 | 2004-12-14 | President And Fellows Of Harvard College | Inhibition of p53 degradation |
| US6348558B1 (en) | 1999-12-10 | 2002-02-19 | Shearwater Corporation | Hydrolytically degradable polymers and hydrogels made therefrom |
| US6579967B1 (en) | 1999-12-14 | 2003-06-17 | The Salk Institute For Biological Studies | Receptor-selective somatostatin analogs |
| US20030087263A1 (en) | 1999-12-16 | 2003-05-08 | Renu Wadhwa | Method of screening remedy for cancer with the use of interaction domain of p53 and mortalin |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| US20010020012A1 (en) | 2000-02-01 | 2001-09-06 | Andersen Maibritt Bansholm | Use of compounds for the regulation of food intake |
| DE10009341A1 (en) | 2000-02-22 | 2001-09-06 | Florian Kern | Method for antigen-specific stimulation of T lymphocytes |
| US6495674B1 (en) | 2000-02-25 | 2002-12-17 | The Salk Institute For Biological Studies | Evectins and their use |
| US20020002198A1 (en) | 2000-04-17 | 2002-01-03 | Parr Tyler B. | Chemical synergy to elevate growth hormone release in vertebrates |
| US6495589B2 (en) | 2000-04-28 | 2002-12-17 | Pfizer Inc. | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor |
| US6897286B2 (en) | 2000-05-11 | 2005-05-24 | Zymogenetics, Inc. | Zsig33-like peptides |
| CA2380423A1 (en) | 2000-05-17 | 2001-11-22 | Bionebraska, Inc. | Peptide pharmaceutical formulations |
| DE60140285D1 (en) | 2000-05-31 | 2009-12-10 | Pfizer Prod Inc | Use of growth hormone secretagogues to promote the mobility of the digestive tract |
| IL143690A0 (en) | 2000-06-19 | 2002-04-21 | Pfizer Prod Inc | The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease |
| IL143942A0 (en) | 2000-06-29 | 2002-04-21 | Pfizer Prod Inc | Use of growth hormone secretagogues for treatment of physical performance decline |
| US7166712B2 (en) | 2000-07-12 | 2007-01-23 | Philadelphia, Health And Education Corporation | Mammalian MDM2 binding proteins and uses thereof |
| IL144468A0 (en) | 2000-07-27 | 2002-05-23 | Pfizer Prod Inc | Use of growth hormone secretagogues for improvement of functional health status |
| US7049290B2 (en) | 2000-07-28 | 2006-05-23 | Universität Zürich | Essential downstream component of the wingless signaling pathway and therapeutic and diagnostic applications based thereon |
| CN1454214A (en) | 2000-08-02 | 2003-11-05 | 赛莱技术公司 | Modified peptides with increased potency |
| US20040228866A1 (en) | 2000-08-04 | 2004-11-18 | Ludwig Institute For Cancer Research | Suppressor genes |
| US6703382B2 (en) | 2000-08-16 | 2004-03-09 | Georgetown University Medical Center | Small molecule inhibitors targeted at Bcl-2 |
| IL145106A0 (en) | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| EP1313473A2 (en) | 2000-08-30 | 2003-05-28 | Pfizer Products Inc. | Sustained release formulations for growth hormone secretagogues |
| MXPA03001451A (en) | 2000-09-08 | 2004-12-13 | Gryphon Therapeutics Inc | Pseudo-native chemical ligation. |
| US6720330B2 (en) | 2000-11-17 | 2004-04-13 | Pfizer Inc. | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor |
| US20030074679A1 (en) | 2000-12-12 | 2003-04-17 | Schwartz Robert J. | Administration of nucleic acid sequence to female animal to enhance growth in offspring |
| CA2432111A1 (en) | 2000-12-19 | 2002-08-22 | The Johns Hopkins University | Jfy1 protein induces rapid apoptosis |
| US20020091090A1 (en) | 2000-12-28 | 2002-07-11 | Cole Bridget M. | Somatostatin antagonists and agonists |
| CU23157A1 (en) | 2001-01-03 | 2006-07-18 | Ct Ingenieria Genetica Biotech | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TISSULAR DANE DUE TO LACK OF BLOOD IRRIGATION ARTERIAL |
| AU2002233082B2 (en) | 2001-02-02 | 2005-11-10 | Conjuchem Biotechnologies Inc. | Long lasting growth hormone releasing factor derivatives |
| ES2527339T3 (en) | 2001-02-23 | 2015-01-23 | Polyphor Ltd. | Pattern-fixed peptidomimetics with antimicrobial activity |
| GB0104588D0 (en) | 2001-02-24 | 2001-04-11 | Univ Dundee | Novel p-53 inducible protein |
| DE10109813A1 (en) | 2001-03-01 | 2002-09-12 | Thomas Stanislawski | Tumor peptide antigen from human mdm2 proto-oncogene |
| US20050054770A1 (en) | 2001-03-09 | 2005-03-10 | Spatola Arno F. | Helicomimetics and stabilized lxxll peptidomimetics |
| US7019109B2 (en) | 2001-03-16 | 2006-03-28 | The Salk Institute For Bilogical Studies | SSTR1-selective analogs |
| KR20030088494A (en) | 2001-04-09 | 2003-11-19 | 더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드 | Somatostatin agonists |
| US6368617B1 (en) | 2001-05-15 | 2002-04-09 | Reliv' International, Inc. | Dietary supplement |
| JP4223390B2 (en) | 2001-06-05 | 2009-02-12 | エラン・ファルマ・インターナショナル・リミテッド | System and method for milling material |
| JP2004536834A (en) | 2001-07-06 | 2004-12-09 | オークランド ユニサーヴィシズ リミテッド | Hypertension treatment |
| EP1422215A4 (en)* | 2001-08-08 | 2005-07-06 | Kaneka Corp | Process for producing optically active 2-substituted carboxylic acid |
| WO2003023000A2 (en) | 2001-09-07 | 2003-03-20 | Baylor College Of Medicine | Linear dna fragments for gene expression |
| US20040106548A1 (en) | 2001-09-07 | 2004-06-03 | Schmidt Michelle A | Conformationally constrained labeled peptides for imaging and therapy |
| US20020045192A1 (en) | 2001-09-19 | 2002-04-18 | St. Jude Children's Research Hospital | Arf and HDM2 interaction domains and methods of use thereof |
| EP1312363A1 (en) | 2001-09-28 | 2003-05-21 | Pfizer Products Inc. | Methods of treatment and kits comprising a growth hormone secretagogue |
| US20030083241A1 (en) | 2001-11-01 | 2003-05-01 | Young Charles W. | Use of somatostatin receptor agonists in the treatment of human disorders of sleep hypoxia and oxygen deprivation |
| CN101157924A (en) | 2001-12-11 | 2008-04-09 | 人体基因组科学有限公司 | Neutrophil leukocyte gene alpha |
| EP1321474A1 (en) | 2001-12-18 | 2003-06-25 | Universite De Geneve | A method for inducing apoptosis |
| US7485620B2 (en) | 2001-12-18 | 2009-02-03 | Alizé Pharma SAS | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof |
| AU2002367160A1 (en) | 2001-12-24 | 2003-07-15 | Auckland Uniservices Limited | Therapy for growth hormone induced insulin resistance in juveniles with growth disorders |
| US7247700B2 (en) | 2001-12-31 | 2007-07-24 | Dana Farber Cancer Institute, Inc. | BID polypeptides and methods of inducing apoptosis |
| WO2003059933A2 (en) | 2002-01-03 | 2003-07-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Conformationally constrained c-backbone cyclic peptides |
| US7250405B2 (en) | 2002-02-07 | 2007-07-31 | Baylor College Of Medicine | Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy |
| AU2003219787A1 (en) | 2002-02-14 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Formulation strategies in stabilizing peptides in organic solvents and in dried states |
| AU2003211093A1 (en) | 2002-02-15 | 2003-09-09 | The Regents Of The University Of Michigan | Inhibitors of rgs proteins |
| US20030166138A1 (en) | 2002-02-21 | 2003-09-04 | Todd Kinsella | Cyclic peptides and analogs useful to treat allergies |
| WO2003081258A2 (en) | 2002-03-26 | 2003-10-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with growth hormone secretagogue receptor (ghs) |
| US7498134B2 (en) | 2002-03-30 | 2009-03-03 | The Trustees Of Columbia University In The City Of New York | HAUSP-Mdm2 interaction and uses thereof |
| EP1499895B1 (en) | 2002-04-22 | 2008-05-07 | University Of Florida | Functionalized nanoparticles and methods of use |
| AU2003235504A1 (en) | 2002-05-13 | 2003-11-11 | 3-Dimensional Pharmaceuticals, Inc. | Method for cytoprotection through mdm2 and hdm2 inhibition |
| CA2487424C (en) | 2002-05-30 | 2011-01-04 | The Scripps Research Institute | Copper-catalysed ligation of azides and acetylenes |
| AU2003247435A1 (en) | 2002-05-30 | 2003-12-19 | European Molecular Biology Laboratory | Combinatorial chemical library ii |
| US7208154B2 (en) | 2002-06-03 | 2007-04-24 | Regents Of The University Of Michigan | Methods and compositions for the treatment of MHC-associated conditions |
| SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| AU2003253883A1 (en) | 2002-07-15 | 2004-02-02 | The Johns Hopkins University | Neuronal and optic nerve gene expression patterns |
| AU2003259172A1 (en) | 2002-07-24 | 2004-02-09 | The Salk Institute For Biological Studies | Receptor (sstr4)- selective somatostatin analogs |
| US20060051846A1 (en) | 2002-09-06 | 2006-03-09 | Kaneka Corporation | Process for producing l-alpha-methylcysteine derivative |
| CA2496400A1 (en) | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
| MXPA05002991A (en) | 2002-09-18 | 2005-10-05 | Univ Montreal Ct Hospitalier Chum | Ghrh analogues. |
| AU2003277891A1 (en) | 2002-09-23 | 2004-04-08 | Medivir Ab | Hcv ns-3 serine protease inhibitors |
| DE60326623D1 (en) | 2002-10-07 | 2009-04-23 | Genome Res Ltd | P53 BINDING POLYPEPTIDE |
| AU2003282755A1 (en) | 2002-10-07 | 2004-05-04 | Zymogenetics, Inc. | Methods of regulating body weight |
| EP1407779A1 (en) | 2002-10-10 | 2004-04-14 | Gastrotech A/S | Use of ghrelin for treating low body weight and body fat in gastrectomized individuals |
| DE10393514T5 (en) | 2002-10-24 | 2005-09-29 | Dow Global Technologies, Inc., Midland | Stabilization of product mixtures from olefin metathesis |
| EP2135868A1 (en) | 2002-11-07 | 2009-12-23 | Kosan Biosciences Incorporated | Trans-9, 10-dehydroepothilone c and d, analogs thereof and methods of making the same |
| BR0316091A (en) | 2002-11-08 | 2005-09-27 | Hoffmann La Roche | Compounds, process for manufacturing them, pharmaceutical compositions, method for treating and / or preventing diseases that are modulated by ppar (a) and / or ppar (y) agonists and / or use thereof |
| US20050227932A1 (en) | 2002-11-13 | 2005-10-13 | Tianbao Lu | Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction |
| US7166575B2 (en) | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
| EP1578798A1 (en) | 2002-12-20 | 2005-09-28 | 7TM Pharma A/S | Ghrelin receptor inverse agonist for regulation of feeding behaviours |
| WO2004058804A1 (en) | 2002-12-24 | 2004-07-15 | Walter And Eliza Hall Institute Of Medical Research | Peptides and therapeutic uses thereof |
| US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
| WO2004067719A2 (en) | 2003-01-28 | 2004-08-12 | Advisys, Inc. | Growth hormone releasing hormone (ghrh) for use in reducing culling in herd animals |
| US20050059605A1 (en) | 2003-01-31 | 2005-03-17 | Krishna Peri | Chemically modified metabolites of regulatory peptides and methods of producing and using same |
| WO2004073729A1 (en) | 2003-02-21 | 2004-09-02 | Translational Research Ltd. | Compositions for nasal administration of drug |
| EP1609802A4 (en) | 2003-02-26 | 2006-06-21 | Japan Science & Tech Agency | TRANSCRIPTIONAL FACTOR INDUCING APOPTOSIS IN A CANCER CELL |
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| US20070060512A1 (en) | 2003-03-04 | 2007-03-15 | Homayoun Sadeghi | Dipeptidyl-peptidase protected protein |
| WO2004084943A1 (en) | 2003-03-19 | 2004-10-07 | Beth Israel Deaconess Medical Center, Inc | Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation |
| US7632920B2 (en) | 2003-04-10 | 2009-12-15 | Schering Corporation | Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof |
| CA2525574C (en) | 2003-05-15 | 2015-06-30 | Trustees Of Tufts College | Stable analogs of peptide and polypeptide therapeutics |
| EP1628676A1 (en) | 2003-05-29 | 2006-03-01 | Theratechnologies Inc. | Grf analog compositions and their use |
| AU2003902743A0 (en) | 2003-06-02 | 2003-06-19 | Promics Pty Limited | Process for the preparation of cyclic peptides |
| MXPA05013340A (en) | 2003-06-09 | 2006-03-09 | Nastech Pharm Co | Compositions and methods for enhanced mucosal delivery of growth hormone. |
| USRE42013E1 (en) | 2003-06-18 | 2010-12-28 | Tranzyme Pharma Inc. | Macrocyclic modulators of the ghrelin receptor |
| US7491695B2 (en) | 2003-06-18 | 2009-02-17 | Tranzyme Pharma Inc. | Methods of using macrocyclic modulators of the ghrelin receptor |
| US20090198050A1 (en) | 2003-06-18 | 2009-08-06 | Tranzyme Pharma Inc. | Macrocyclic Modulators of the Ghrelin Receptor |
| ES2338789T3 (en) | 2003-06-18 | 2010-05-12 | Tranzyme Pharma Inc. | MACROCICLIC ANTAGONISTS OF THE MOTILINA RECEPTOR. |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| USRE42624E1 (en) | 2003-06-18 | 2011-08-16 | Tranzyme Pharma Inc. | Methods of using macrocyclic modulators of the ghrelin receptor |
| WO2005000876A2 (en) | 2003-06-27 | 2005-01-06 | Proteologics, Inc. | Ring finger family proteins and uses related thereto |
| WO2005007675A2 (en) | 2003-07-09 | 2005-01-27 | The Scripps Research Institute | TRIAZOLE ϵ-AMINO ACIDS |
| US20070185031A1 (en) | 2003-07-14 | 2007-08-09 | Northwestern University | Reducing polyglutamine-based aggregation |
| GB0317815D0 (en) | 2003-07-30 | 2003-09-03 | Amersham Health As | Imaging agents |
| US7695426B2 (en) | 2003-08-20 | 2010-04-13 | Biological Resources Pty Ltd | Methods for enhancing viability |
| WO2005018682A2 (en) | 2003-08-20 | 2005-03-03 | The Regents Of The University Of California | Somatostatin analogs with inhibitory activity to growth hormone release |
| WO2005027913A1 (en) | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue |
| ATE396973T1 (en) | 2003-10-03 | 2008-06-15 | Merck & Co Inc | BENZYL ETHER AND BENZYLAMINO BETA SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| CN1938018B (en) | 2003-10-03 | 2010-09-01 | 维伊林股份有限公司 | Use of compounds for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced igf-1 serum level |
| GB0323728D0 (en) | 2003-10-10 | 2003-11-12 | Royal College Of Surgeons Ie | Peptidomimetics and uses thereof |
| EP1673386A2 (en) | 2003-10-16 | 2006-06-28 | AplaGen GmbH | Stabilized alpha-helical peptides |
| US20070274915A1 (en) | 2003-10-17 | 2007-11-29 | Anjana Rao | Modulation Of Anergy And Methods For isolating Anergy-Modulating Compounds |
| EP1675610A4 (en) | 2003-10-20 | 2010-04-28 | Theratechnologies Inc | USE OF SOMATOSTATIN ANALOGS IN THE TREATMENT OF PATIENTS SUFFERING FROM CACHEXIA |
| US7273927B2 (en) | 2003-11-03 | 2007-09-25 | University Of Massachusetts | Mdm2 splice variants |
| ES2586387T3 (en) | 2003-11-05 | 2016-10-14 | Dana-Farber Cancer Institute, Inc. | Suitable alpha helical peptides to activate or inhibit cell death |
| US20050147581A1 (en) | 2003-11-19 | 2005-07-07 | The Board Of Trustees Of The University Of Illinois | Macromolecular drug complexes having improved stability and therapeutic use of the same |
| WO2005074521A2 (en) | 2004-01-30 | 2005-08-18 | The Trustees Of Columbia University In The City Of New York | C-TERMINAL p53 PALINDROMIC PEPTIDE THAT INDUCES APOPTOSIS OF CELLS WITH ABERRANT p53 AND USES THEREOF |
| US20070161551A1 (en) | 2004-02-10 | 2007-07-12 | De Luca Giampiero | Methods and compositions for the treatment of lipodystrophy |
| GB0404731D0 (en) | 2004-03-03 | 2004-04-07 | Indp Administrative Inst Nims | Method and products for the selective degradation of proteins |
| US20050203009A1 (en) | 2004-03-12 | 2005-09-15 | Bayer Pharmaceuticals Corporation | VPAC1 selective antagonists and their pharmacological methods of use |
| EP1737884B1 (en) | 2004-03-19 | 2016-10-19 | The University Of Queensland | Alpha helical mimics, their uses and methods for their production |
| KR20070010151A (en) | 2004-03-30 | 2007-01-22 | 사파이어 세라퓨틱스, 인크. | How to reduce C-reactive protein using growth hormone secretagogue |
| JP2007532495A (en) | 2004-04-07 | 2007-11-15 | ガストロテック・ファルマ・アクティーゼルスカブ | Use of secretagogues to treat ghrelin deficiency |
| US7034050B2 (en) | 2004-04-28 | 2006-04-25 | Romano Deghenghi | Pseudopeptides growth hormone secretagogues |
| KR100832277B1 (en) | 2004-05-18 | 2008-05-26 | 에프. 호프만-라 로슈 아게 | Novel cis-imidazolines |
| US7202332B2 (en) | 2004-05-27 | 2007-04-10 | New York University | Methods for preparing internally constrained peptides and peptidomimetics |
| WO2005118634A2 (en) | 2004-06-04 | 2005-12-15 | The Brigham And Women's Hospital, Inc. | Helical peptidomimetics with enhanced activity against beta-amyloid production |
| CN100335467C (en) | 2004-06-04 | 2007-09-05 | 中国科学院上海有机化学研究所 | Synthesis of 5-iodo-1,4-twice substituted-1,2,3-trioxazole compound |
| EP1602663A1 (en) | 2004-06-04 | 2005-12-07 | Chiralix B.V. | Triazole-linked glycoamino acids and glycopeptides |
| US7893278B2 (en) | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
| CN102603895B (en) | 2004-06-18 | 2016-09-28 | Ambrx公司 | Novel antigen-binding polypeptides and its purposes |
| US7674787B2 (en) | 2004-07-09 | 2010-03-09 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
| EP1789067B8 (en) | 2004-08-12 | 2012-08-15 | Helsinn Healthcare S.A. | Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system |
| US8039456B2 (en) | 2004-08-12 | 2011-10-18 | Helsinn Therapeutics (U.S.), Inc. | Method of stimulating the motility of the gastrointestinal system using ipamorelin |
| EP2389941A1 (en) | 2004-08-18 | 2011-11-30 | Elixir Pharmaceuticals, Inc. | Growth-hormone secretagogues |
| US7074775B2 (en) | 2004-09-14 | 2006-07-11 | Miller Landon C G | Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders |
| US7157421B2 (en) | 2004-12-27 | 2007-01-02 | Miller Landon C G | Piracetam and piracetam analog conjugate and a pharmaceutical composition for treatment of neuronal disorders |
| US7402652B2 (en) | 2004-09-14 | 2008-07-22 | Miller Landon C G | Baclofen conjugate and a pharmaceutical composition for treatment of neuronal disorders |
| US7151084B2 (en) | 2004-12-27 | 2006-12-19 | Miller Landon C G | Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes |
| US9598470B2 (en) | 2004-10-07 | 2017-03-21 | Craig W. Beattie | Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways |
| AU2005297366B2 (en) | 2004-10-20 | 2011-12-08 | Theratechnologies Inc. | GH secretagogues and uses thereof |
| CN101087762A (en) | 2004-10-29 | 2007-12-12 | 先灵公司 | Substituted 5-carboxamide pyrazoles and [1,2,4]triazoles as antiviral agents |
| US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
| US20060148715A1 (en) | 2004-12-20 | 2006-07-06 | Baylor College Of Medicine | Structural requirements for STAT3 binding and recruitment to phosphotyrosine ligands |
| GB0428187D0 (en) | 2004-12-23 | 2005-01-26 | Univ Liverpool | Cancer treatment |
| WO2006078161A1 (en) | 2005-01-24 | 2006-07-27 | Pepscan Systems B.V. | Binding compounds, immunogenic compounds and peptidomimetics |
| FR2881430B1 (en) | 2005-02-01 | 2010-10-22 | Servier Lab | NOVEL PEPTIDES INTERACTING WITH ANTI-APOPTOTIC MEMBERS OF THE BCL-2 PROTEIN FAMILY AND USES THEREOF |
| NZ561215A (en) | 2005-02-22 | 2010-12-24 | Univ Michigan | Small molecule inhibitors of MDM2 and uses thereof |
| CA2601592A1 (en) | 2005-03-15 | 2006-09-28 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
| WO2006103666A2 (en) | 2005-03-28 | 2006-10-05 | Yeda Research And Development Co. Ltd. | Isolated bid polypeptides, polynucleotides encoding same and antibodies directed thereagainst and methods of using same for inducing cell cycle arrest or apoptosis |
| WO2006122931A1 (en) | 2005-05-20 | 2006-11-23 | Biovitrum Ab (Publ) | Beta-carboline derivatives and theri use as ghsr modulators |
| EP1891090A2 (en) | 2005-06-13 | 2008-02-27 | Tranzyme Pharma, Inc. | Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same |
| US20090275648A1 (en) | 2005-06-13 | 2009-11-05 | Fraser Graeme L | Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same |
| US20070020620A1 (en) | 2005-07-14 | 2007-01-25 | Finn M G | Compositions and methods for coupling a plurality of compounds to a scaffold |
| EP1909854A4 (en) | 2005-07-21 | 2012-02-22 | Barry John Allen | Method for treating cancer |
| JP4879265B2 (en) | 2005-07-22 | 2012-02-22 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | Growth hormone secretagogue |
| EP1757290A1 (en) | 2005-08-16 | 2007-02-28 | Zentaris GmbH | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors |
| ES2474643T3 (en) | 2005-09-28 | 2014-07-09 | Ipsen Pharma | Ghrelin analogues |
| US20070161544A1 (en) | 2006-01-06 | 2007-07-12 | Peter Wipf | Selective targeting agents for mitcochondria |
| WO2007095347A2 (en) | 2006-02-13 | 2007-08-23 | The Gov. Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Methods and compositions related to ghs-r antagonists |
| US7745573B2 (en) | 2006-02-17 | 2010-06-29 | Polychip Pharmaceuticals Pty Ltd. | Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides |
| US7538190B2 (en) | 2006-02-17 | 2009-05-26 | Polychip Pharmaceuticals Pty Ltd | Methods for the synthesis of two or more dicarba bridges in organic compounds |
| GB0603295D0 (en) | 2006-02-18 | 2006-03-29 | Ardana Bioscience Ltd | Methods and kits |
| CU23592A1 (en) | 2006-02-28 | 2010-11-11 | Ct Ingenieria Genetica Biotech | METHOD TO PREVENT AND ELIMINATE FIBROSIS AND OTHER FORMS OF PATHOLOGICAL DEPOSIT IN THE FABRICS APPLYING THE GHRP-6 SECRETAGOGO PEPTIDE |
| CN101443358B (en) | 2006-03-13 | 2016-05-11 | 利亚特·明茨 | Use of ghrelin splice variants for the treatment of cachexia and/or bulimia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation |
| US20100179168A1 (en) | 2006-04-13 | 2010-07-15 | Emma Louise Blaney | Aryl and heteroaryl sulphonamides as growth hormone secretagogue receptor agonists |
| EP2021015A2 (en) | 2006-04-28 | 2009-02-11 | The Administrators Of The Tulane Educational Fund | Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof |
| GB0611405D0 (en) | 2006-06-09 | 2006-07-19 | Univ Belfast | FKBP-L: A novel inhibitor of angiogenesis |
| US7998927B2 (en) | 2006-06-23 | 2011-08-16 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| US8173594B2 (en) | 2006-06-23 | 2012-05-08 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| US7425542B2 (en) | 2006-06-23 | 2008-09-16 | Aegis Therapeutics, Inc. | Stabilizing alkylglycoside compositions and methods thereof |
| US8084022B2 (en) | 2006-06-23 | 2011-12-27 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| US20090326193A1 (en) | 2006-06-23 | 2009-12-31 | Aegis Therapeutics Llc | Stabilizing alkylglycoside compositions and methods thereof |
| US8226949B2 (en) | 2006-06-23 | 2012-07-24 | Aegis Therapeutics Llc | Stabilizing alkylglycoside compositions and methods thereof |
| AU2007269836A1 (en) | 2006-06-30 | 2008-01-10 | Albany Molecular Research, Inc. | Substituted piperidines that increase P53 activity and the uses thereof |
| CA2656393A1 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Method of using substituted piperidines that increase p53 activity |
| US8088733B2 (en) | 2006-07-06 | 2012-01-03 | Tranzyme Pharma Inc. | Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders |
| WO2008008357A1 (en) | 2006-07-11 | 2008-01-17 | Harkness Pharmaceuticals, Inc. | Methods of treating obesity using satiety factors |
| AU2007277556B2 (en) | 2006-07-26 | 2012-11-29 | Pepscan Systems B.V. | Immunogenic compounds and protein mimics |
| US8614192B2 (en) | 2006-07-28 | 2013-12-24 | Leiden University Medical Center | Method for treating ocular cancer |
| US7737174B2 (en) | 2006-08-30 | 2010-06-15 | The Regents Of The University Of Michigan | Indole inhibitors of MDM2 and the uses thereof |
| EP2099445B1 (en) | 2006-09-04 | 2010-11-17 | University Court of The University of Dundee | P53 activating benzoyl urea and benzoyl thiourea compounds |
| WO2008033557A2 (en) | 2006-09-15 | 2008-03-20 | Siemens Medical Solutions Usa, Inc. | Click chemistry-derived cyclic peptidomimetics as integrin markers |
| BRPI0717266A2 (en) | 2006-09-21 | 2014-12-09 | Hoffmann La Roche | OXINDOL DERIVATIVES |
| US7897394B2 (en) | 2006-09-21 | 2011-03-01 | Intrexon Corporation | Endoplasmic reticulum localization signals |
| ES2436419T3 (en) | 2006-09-27 | 2014-01-02 | Ipsen Pharma S.A.S. | Ghrelin analogs substituted at the N-terminus |
| EP2517720A1 (en) | 2006-10-05 | 2012-10-31 | New York Blood Center, Inc. | Stabilized therapeutic small helical antiviral peptides |
| KR100860060B1 (en) | 2006-10-12 | 2008-09-24 | 한국과학기술연구원 | Quantitative analysis of binding of HIF-1α C-terminal peptide to CBP or P300 protein and screening method of inhibitor that inhibits protein complex formation using the method |
| ES2526292T3 (en) | 2006-10-16 | 2015-01-09 | The Salk Institute For Biological Studies | Somatostatin receptor selective antagonists (SSTR2) |
| US8691761B2 (en) | 2006-10-16 | 2014-04-08 | Jean E. F. Rivier | Somatostatin receptor 2 antagonists |
| EP2997973A1 (en) | 2006-11-15 | 2016-03-23 | Dana-Farber Cancer Institute, Inc. | Stabalized maml peptides and uses thereof |
| US7932397B2 (en) | 2006-11-22 | 2011-04-26 | Massachusetts Institute Of Technology | Olefin metathesis catalysts and related methods |
| US7981998B2 (en) | 2006-12-14 | 2011-07-19 | Aileron Therapeutics, Inc. | Bis-sulfhydryl macrocyclization systems |
| CN105061577A (en) | 2006-12-14 | 2015-11-18 | 爱勒让治疗公司 | Bis-sulfhydryl macrocyclization systems |
| AU2007336132A1 (en) | 2006-12-21 | 2008-06-26 | Cytos Biotechnology Ag | Circular CCR5 peptide conjugates and uses thereof |
| EP2114986B1 (en) | 2007-01-29 | 2013-05-22 | Polyphor Ltd. | Template-fixed peptidomimetics |
| PL2118123T3 (en) | 2007-01-31 | 2016-06-30 | Dana Farber Cancer Inst Inc | Stabilized p53 peptides and uses thereof |
| ES2602789T3 (en) | 2007-02-09 | 2017-02-22 | Ocera Therapeutics, Inc. | Connector intermediates for the synthesis of macrocyclic modulators of the ghrelin receptor |
| US7981999B2 (en) | 2007-02-23 | 2011-07-19 | Aileron Therapeutics, Inc. | Triazole macrocycle systems |
| WO2008106507A2 (en) | 2007-02-27 | 2008-09-04 | University Of South Florida | Mdm2/mdmx inhibitor peptide |
| WO2008112938A2 (en) | 2007-03-13 | 2008-09-18 | New England Medical Center Hospitals, Inc. | Composition and method for the treatment of diseases affected by a peptide receptor |
| EP3159352B1 (en) | 2007-03-28 | 2023-08-02 | President and Fellows of Harvard College | Stitched polypeptides |
| TWI429436B (en) | 2007-04-10 | 2014-03-11 | Helsinn Therapeutics Us Inc | Methods of treating or preventing emesis using growth hormone secretagogues |
| US20080260820A1 (en) | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
| ES2637687T3 (en) | 2007-05-02 | 2017-10-16 | Dana-Farber Cancer Institute, Inc. | BAD peptide of BH3 domain for use in the treatment or delay of the onset of diabetes |
| CA2687246A1 (en) | 2007-06-01 | 2008-12-11 | Acologix, Inc. | High temperature stable peptide formulation |
| WO2009009727A2 (en) | 2007-07-12 | 2009-01-15 | Akela Pharma Srl | Ghrh analogs and therapeutic uses thereof |
| RU2007133287A (en) | 2007-09-05 | 2009-03-10 | Ионов Иль Давидович (RU) | ANTIPOPSORIATIC AGENT AND METHOD OF ITS USE (OPTIONS) |
| EP2185182A1 (en) | 2007-09-11 | 2010-05-19 | Mondobiotech Laboratories AG | Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents |
| EP2227244A1 (en) | 2007-09-11 | 2010-09-15 | Mondobiotech Laboratories AG | Cgrp as a therapeutic agent |
| WO2009040024A2 (en) | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| EP2197431A4 (en) | 2007-09-17 | 2013-03-27 | Olas Pharmaceuticals Inc | Modulation of growth hormone, dhea, and cortisol with positive modulators of ampa type glutamate receptors |
| WO2009037343A1 (en) | 2007-09-21 | 2009-03-26 | Janssen Pharmaceutica Nv | Inhibitors of the interaction between mdm2 and p53 |
| WO2009042237A2 (en) | 2007-09-26 | 2009-04-02 | Dana Farber Cancer Institute | Methods and compositions for modulating bcl-2 family polypeptides |
| ES2431573T3 (en) | 2007-12-03 | 2013-11-27 | Italfarmaco S.P.A. | New non-selective somatostatin analogues |
| JP5653219B2 (en) | 2007-12-31 | 2015-01-14 | ニューヨーク ユニバーシティ | Control of viral host membrane fusion by an artificial helix based on hydrogen-bonded surrogates |
| DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
| MX2010008168A (en) | 2008-01-25 | 2011-02-24 | P53 Inc | P53 biomarkers. |
| CN103951541A (en) | 2008-01-25 | 2014-07-30 | 波士顿学院董事会 | Method for catalyzing metathesis reactons including enantioselective olefin metathesis |
| CN101980718A (en) | 2008-02-08 | 2011-02-23 | 爱勒让治疗公司 | Therapeutic peptidomimetic macrocycles |
| EP2310407A4 (en) | 2008-04-08 | 2011-09-14 | Aileron Therapeutics Inc | BIOLOGIC EFFECTIVE PEPTIDOMIMETIC MACROCYCLES |
| US20110144303A1 (en) | 2008-04-08 | 2011-06-16 | Aileron Therapeutics, Inc. | Biologically Active Peptidomimetic Macrocycles |
| CA2725227A1 (en) | 2008-05-06 | 2009-11-12 | Asim Kumar Debnath | Antiviral cell penetrating peptides |
| WO2009149214A2 (en) | 2008-06-03 | 2009-12-10 | Aileron Therapeutics, Inc. | Compositions and methods for enhancing cellular transport of biomolecules |
| US8343760B2 (en) | 2008-06-05 | 2013-01-01 | University Of Maryland, Baltimore | p53 activator peptides |
| KR101731655B1 (en) | 2008-06-12 | 2017-05-11 | 입센 바이오이노베이션 리미티드 | Suppression of cancers |
| AU2009259033B2 (en) | 2008-06-12 | 2013-11-07 | Ipsen Bioinnovation Limited | Suppression of neuroendocrine diseases |
| US8796216B2 (en) | 2008-06-12 | 2014-08-05 | Syntaxin Limited | Suppression of neuroendocrine diseases |
| US20110158973A1 (en) | 2008-06-12 | 2011-06-30 | Syntaxin Limited | Suppression of cancers |
| AU2009262243B2 (en) | 2008-06-25 | 2015-01-29 | Braasch Biotech Llc | Compositions and methods for enhanced somatostatin immunogenicity |
| US20110144306A1 (en) | 2008-07-23 | 2011-06-16 | President And Fellows Of Harvard College | Ligation of stapled polypeptides |
| GB0813873D0 (en) | 2008-07-30 | 2008-09-03 | Univ Dundee | Compounds |
| EP3216874A1 (en) | 2008-09-05 | 2017-09-13 | TOMA Biosciences, Inc. | Methods for stratifying and annotating cancer drug treatment options |
| US8586707B2 (en) | 2008-09-16 | 2013-11-19 | The Research Foundation Of State University Of New York | Stapled peptides and method of synthesis |
| EP2344520B1 (en) | 2008-09-18 | 2013-11-13 | New York University | Inhibiting interaction between hif-1a and p300/cbp with hydrogen bond surrogate-based helices |
| AU2009292643B2 (en) | 2008-09-19 | 2016-02-18 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
| WO2010034029A1 (en) | 2008-09-22 | 2010-03-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| US20120101047A1 (en) | 2008-09-22 | 2012-04-26 | Aileron Therapetics Inc. | Peptidomimetic macrocycles |
| JP2012510430A (en) | 2008-09-22 | 2012-05-10 | エルロン・セラピューティクス・インコーポレイテッド | Peptidomimetic macrocycle |
| JP5711128B2 (en) | 2008-09-22 | 2015-04-30 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | Peptidomimetic macrocycle |
| AU2009294875C1 (en) | 2008-09-22 | 2015-05-14 | Aileron Therapeutics, Inc. | Methods for preparing purified polypeptide compositions |
| CN102197046A (en) | 2008-09-22 | 2011-09-21 | 爱勒让治疗公司 | Peptidomimetic marcrocycles |
| WO2010042225A2 (en) | 2008-10-10 | 2010-04-15 | Dana Farber Cancer Institute | Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides |
| JP2010120881A (en) | 2008-11-19 | 2010-06-03 | Keio Gijuku | PEPTIDE FOR INHIBITING INTERACTION BETWEEN HUMAN CANCER PROTEIN MDM2 AND HUMAN CANCER-INHIBITING PROTEIN p53, AND USE THEREOF |
| KR101298168B1 (en) | 2008-11-21 | 2013-08-20 | 충남대학교산학협력단 | Chemical inhibitor of snail―ｐ５３ binding and pharmaceutical composition for treating cancer disease comprising the same |
| EP2352507A4 (en) | 2008-11-24 | 2012-04-25 | Aileron Therapeutics Inc | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES |
| WO2010065572A1 (en) | 2008-12-04 | 2010-06-10 | The Salk Institute For Biological Studies | Sstr1-selective analogs |
| EP3549951A3 (en) | 2008-12-09 | 2019-11-20 | Dana Farber Cancer Institute, Inc. | Methods and compositions for specific modulation of mcl-1 |
| US20100152114A1 (en) | 2008-12-12 | 2010-06-17 | Univ Of Miami And Usa By Dept Of Veterans Affairs | Antioxidant activity of GH-RH Antagonists |
| JP2012515172A (en) | 2009-01-14 | 2012-07-05 | エルロン・セラピューティクス・インコーポレイテッド | Peptidomimetic macrocycle |
| WO2010083501A2 (en) | 2009-01-16 | 2010-07-22 | University Of South Florida | Alpha-helix mimetic using a 2,5-oligopyrimidine scaffold |
| US8217051B2 (en) | 2009-02-17 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| US20100239589A1 (en) | 2009-02-23 | 2010-09-23 | Salk Institute For Biological Studies | Methods and Compositions for Ameliorating Diabetes and Symptoms Thereof |
| FR2942798B1 (en) | 2009-03-05 | 2011-04-08 | Centre Nat Rech Scient | PEPTIDES USEFUL FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA |
| US20120135089A1 (en) | 2009-03-17 | 2012-05-31 | Stockwell Brent R | E3 ligase inhibitors |
| WO2010121352A1 (en) | 2009-04-20 | 2010-10-28 | Theratechnologies Inc. | Use of (hexenoyl trans-3)hgrf(l-44)nh2 and simvastatin in combination therapy |
| US8076482B2 (en) | 2009-04-23 | 2011-12-13 | Hoffmann-La Roche Inc. | 3,3′-spiroindolinone derivatives |
| CA2761901C (en) | 2009-05-12 | 2019-08-13 | The Administrators Of The Tulane Educational Fund | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof |
| CN101565390A (en)* | 2009-05-27 | 2009-10-28 | 北京欧凯纳斯科技有限公司 | Method for preparing Alpha-methyl-Alpha, Alpha-disubstituted-Alpha-aminophenol and derivatives thereof |
| US20100303791A1 (en) | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases |
| US20100303794A1 (en) | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases |
| WO2012006598A2 (en)* | 2010-07-09 | 2012-01-12 | Dana-Farber Cancer Institute, Inc. | Stabilized insulinotropic peptides and methods of use |
| WO2011005219A1 (en) | 2009-07-07 | 2011-01-13 | Agency For Science, Technology And Research | Novel mdm2 binding peptides and uses thereof |
| EP2453908B1 (en) | 2009-07-13 | 2018-03-14 | President and Fellows of Harvard College | Bifunctional stapled polypeptides and uses thereof |
| JP2013503129A (en) | 2009-08-26 | 2013-01-31 | ノバルティス アーゲー | Tetra-substituted heteroaryl compounds and their use as MDM2 and / or MDM4 modulators |
| CA2774973A1 (en) | 2009-09-22 | 2011-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| EP2482813A4 (en) | 2009-09-30 | 2013-02-27 | Tranzyme Pharma Inc | Salts, solvates, and pharmaceutical compositions of macrocyclic ghrelin receptor agonists and methods of using the same |
| US8017607B2 (en) | 2009-10-14 | 2011-09-13 | Hoffmann-La Roche Inc. | N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions |
| WO2011047215A1 (en) | 2009-10-14 | 2011-04-21 | Aileron Therapeutics, Inc. | Improved peptidomimetic macrocycles |
| CA2778990A1 (en) | 2009-10-30 | 2011-05-05 | Tranzyme Pharma, Inc. | Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same |
| US20120283269A1 (en) | 2009-11-04 | 2012-11-08 | Health Research Inc. | Method and Compositions for Suppression of Aging |
| AU2010319595B2 (en) | 2009-11-12 | 2015-09-17 | The Regents Of The University Of Michigan | Spiro-oxindole MDM2 antagonists |
| US20110118283A1 (en) | 2009-11-17 | 2011-05-19 | Qingjie Ding | Substituted Pyrrolidine-2-Carboxamides |
| US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| CU24130B1 (en) | 2009-12-22 | 2015-09-29 | Novartis Ag | ISOQUINOLINONES AND REPLACED QUINAZOLINONES |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| US8658170B2 (en) | 2010-01-06 | 2014-02-25 | Joseph P. Errico | Combination therapy with MDM2 and EFGR inhibitors |
| KR101220516B1 (en) | 2010-01-21 | 2013-01-10 | 연세대학교 산학협력단 | Human Adult Stem Cells Secreting Anti-MDM2 and Uses thereof |
| EP2534140B1 (en) | 2010-02-08 | 2018-04-11 | Trustees of Boston College | Efficient methods for z- or cis-selective cross-metathesis |
| US8288431B2 (en) | 2010-02-17 | 2012-10-16 | Hoffmann-La Roche Inc. | Substituted spiroindolinones |
| WO2011106650A2 (en) | 2010-02-27 | 2011-09-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease |
| WO2011127058A2 (en) | 2010-04-09 | 2011-10-13 | The Regents Of The University Of Michigan | Biomarkers for mdm2 inhibitors for use in treating disease |
| US9782454B2 (en) | 2010-04-22 | 2017-10-10 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
| WO2011143209A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
| US9145451B2 (en) | 2010-05-13 | 2015-09-29 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhbiting G protein coupled receptor activity |
| WO2011153491A2 (en) | 2010-06-03 | 2011-12-08 | University Of Miami | Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets |
| US9315546B2 (en) | 2010-06-16 | 2016-04-19 | The Administrators Of The Tulane Educational Fund | Growth hormone secretatogue receptor antagonists and uses thereof |
| US20110313167A1 (en) | 2010-06-22 | 2011-12-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Substituted Heterocycles as Therapeutic agents for treating cancer |
| WO2011163423A2 (en) | 2010-06-22 | 2011-12-29 | University Of Central Florida Research Foundation, Inc. | Methods and compositions for cell permeable stat3 inhibitor |
| EP2588126A4 (en) | 2010-06-24 | 2015-07-08 | Univ Indiana Res & Tech Corp | GLUCAGON SUPERFAMILY AMIDE PEPTIDE PRODRUGS |
| RU2013102991A (en) | 2010-06-24 | 2014-08-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | DIPEPTIDE-related MEDICINES |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| US20130137645A1 (en) | 2010-07-19 | 2013-05-30 | Mary S. Rosendahl | Modified peptides and proteins |
| US8975232B2 (en) | 2010-07-29 | 2015-03-10 | President And Fellows Of Harvard College | Macrocyclic kinase inhibitors and uses thereof |
| WO2012021874A1 (en) | 2010-08-13 | 2012-02-16 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles with thioether linkers |
| AU2011299551A1 (en) | 2010-09-08 | 2013-03-21 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | P53-Mdm2 antagonists |
| US20120065210A1 (en) | 2010-09-15 | 2012-03-15 | Xin-Jie Chu | Substituted hexahydropyrrolo[1,2-c]imidazolones |
| EP2616095A4 (en) | 2010-09-16 | 2014-03-19 | Univ Miami | ACCELERATING WOUND HEALING WITH HORMONE FOR RELEASE OF GROWTH HORMONE AND AGONISTS |
| EP2431035A1 (en) | 2010-09-16 | 2012-03-21 | Æterna Zentaris GmbH | Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors |
| CN102399283B (en) | 2010-09-17 | 2013-05-29 | 中国农业大学 | Mink Growth Hormone Releasing Hormone cDNA and Its Application |
| CN102399284B (en) | 2010-09-17 | 2013-05-29 | 中国农业大学 | Fox Growth Hormone Releasing Hormone cDNA and Its Application |
| US20120071499A1 (en) | 2010-09-20 | 2012-03-22 | Xin-Jie Chu | Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones |
| US8957026B2 (en) | 2010-09-22 | 2015-02-17 | President And Fellows Of Harvard College | Beta-catenin targeting peptides and uses thereof |
| US20130225603A1 (en) | 2010-09-27 | 2013-08-29 | Serrata Llc | Mdm2 inhibitors for treatment of ocular conditions |
| EP2621275B1 (en) | 2010-09-30 | 2018-03-28 | St. Jude Children's Research Hospital | Aryl-substituted imidazoles |
| WO2012051405A1 (en) | 2010-10-13 | 2012-04-19 | Bristol-Myers Squibb Company | Methods for preparing macrocycles and macrocycle stabilized peptides |
| FR2967072B1 (en) | 2010-11-05 | 2013-03-29 | Univ Dundee | PROCESS FOR IMPROVING INFLUENZA PRODUCTION OF VACCINE AND SEEDS |
| WO2012065022A2 (en) | 2010-11-12 | 2012-05-18 | The Regents Of The University Of Michigan | Spiro-oxindole mdm2 antagonists |
| EP2637680B1 (en) | 2010-11-12 | 2017-03-01 | Dana-Farber Cancer Institute, Inc. | Cancer therapies |
| WO2012076513A1 (en) | 2010-12-09 | 2012-06-14 | F. Hoffmann-La Roche Ag | 3-cyano-1-hydroxymethyl-2-phenylpyrrolidine derivatives as inhibitors of mdm2-p53 interactions useful for the treatment of cancer |
| EP2651964B1 (en) | 2010-12-15 | 2018-02-28 | The Research Foundation of State University of New York | Cross-linked peptides and proteins, methods of making same, and uses thereof |
| BR112013014522A2 (en) | 2010-12-16 | 2017-09-26 | Roche Glycart Ag | afucosylated anti-cd20 antibody and its use, composition and method for treating a cancer patient |
| WO2012083181A1 (en) | 2010-12-16 | 2012-06-21 | Indiana University Research And Technology Corporation | Alpha helix mimetics and methods for using |
| EP2651921A1 (en) | 2010-12-17 | 2013-10-23 | Syngenta Participations AG | Insecticidal compounds |
| EP2474625B1 (en) | 2011-01-05 | 2016-11-02 | Daniela Kandioler | Method for determining the p53 status of a tumour |
| EP2474624B1 (en) | 2011-01-05 | 2016-08-17 | Daniela Kandioler | Response prediction in cancer treatment (p53 adapted cancer therapy) |
| WO2012094755A1 (en) | 2011-01-14 | 2012-07-19 | Theratechnologies Inc. | Assessment of igf-1 levels in hiv-infected subjects and uses thereof |
| JP5950587B2 (en) | 2011-02-28 | 2016-07-13 | キヤノン株式会社 | Method for producing porous glass and method for producing optical member |
| US8987412B2 (en) | 2011-03-04 | 2015-03-24 | New York University | Hydrogen bond surrogate macrocycles as modulators of Ras |
| JP6150726B2 (en) | 2011-03-09 | 2017-06-21 | Jitsubo株式会社 | Cross-linked peptide containing a novel non-peptidic cross-linked structure, method for synthesizing the cross-linked peptide, and novel organic compound used in the method |
| LT2684880T (en) | 2011-03-10 | 2018-04-25 | Daiichi Sankyo Company, Limited | Dispiropyrrolidine derivative |
| CA2834657A1 (en) | 2011-04-29 | 2012-11-01 | Kinemed, Inc. | Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents |
| WO2012173846A2 (en) | 2011-06-06 | 2012-12-20 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| EP2721061A4 (en) | 2011-06-17 | 2014-11-05 | Harvard College | STABILIZED VARIANT MAML PEPTIDES AND USES THEREOF |
| WO2012174423A1 (en) | 2011-06-17 | 2012-12-20 | President And Fellows Of Harvard College | Stabilized polypeptides as regulators of rab gtpase function |
| GB201110390D0 (en) | 2011-06-20 | 2011-08-03 | Medical Res Council | Compounds for use in stabilising p53 mutants |
| US20120328692A1 (en) | 2011-06-24 | 2012-12-27 | University Of Maryland, Baltimore | Potent d-peptide antagonists of mdm2 and mdmx for anticancer therapy |
| AU2012301605A1 (en) | 2011-08-31 | 2014-04-17 | New York University | Thioether-,ether-, and alkylamine-linked hydrogen bond surrogate pertidomimentics |
| WO2013036208A1 (en) | 2011-09-09 | 2013-03-14 | Agency For Science, Technology And Research | P53 activating peptides |
| AU2012316055B2 (en) | 2011-09-27 | 2016-05-12 | Amgen Inc. | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer |
| WO2013059530A2 (en) | 2011-10-18 | 2013-04-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| EP2768518A4 (en) | 2011-10-18 | 2015-05-27 | Aileron Therapeutics Inc | PEPTIDOMIMETIC MACROCYCLES |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| CA2761253A1 (en) | 2011-12-07 | 2013-06-07 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| CN104159595A (en) | 2012-02-15 | 2014-11-19 | 爱勒让治疗公司 | Peptidomimetic macrocycles |
| JP6450192B2 (en) | 2012-02-15 | 2019-01-09 | エイルロン セラピューティクス，インコーポレイテッド | Triazole-bridged and thioether-bridged peptidomimetic macrocycles |
| WO2013130791A1 (en) | 2012-02-29 | 2013-09-06 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the identification, assessment, prevention, and therapy of cancer |
| WO2013131019A1 (en) | 2012-03-02 | 2013-09-06 | Ludwig Institute For Cancer Research Ltd. | Iaspp phosphorylation and metastatic potential |
| US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
| EP2844249A4 (en) | 2012-05-02 | 2016-03-09 | Univ Kansas State | MACROCYCLIC AND PEPTIDOMIMETIC COMPOUNDS AS BROAD-SPECTRUM ANTIVIRALS AGAINST 3C OR 3C PROTEINS OF PICORNAVIRUS, CALICIVIRUS AND CORONAVIRUS |
| US20150159222A1 (en) | 2012-07-31 | 2015-06-11 | Novartis Ag | Markers associated with human double minute 2 inhibitors |
| SI2920197T1 (en) | 2012-09-26 | 2021-08-31 | President And Fellows Of Harvard College | Proline-locked stapled peptides and uses thereof |
| WO2014055564A1 (en) | 2012-10-01 | 2014-04-10 | President And Fellows Of Harvard College | Stabilized polypeptide insulin receptor modulators |
| WO2014071241A1 (en) | 2012-11-01 | 2014-05-08 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
| WO2014138429A2 (en) | 2013-03-06 | 2014-09-12 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and use thereof in regulating hif1alpha |
| EP2991665A4 (en) | 2013-03-13 | 2016-11-09 | Harvard College | AGRAFES AND SUTURE POLYPEPTIDES AND USES THEREOF |
| CN105102635B (en) | 2013-03-15 | 2020-09-25 | 生命技术公司 | Classification and feasibility index of Lung cancer |
| US9198910B2 (en) | 2013-04-04 | 2015-12-01 | The Translational Genomics Research Institute | Methods for the treatment of cancer |
| ES2782003T3 (en) | 2013-04-16 | 2020-09-09 | Memorial Sloan Kettering Cancer Center | Diagnostic Companion for CDK4 Inhibitors |
| AU2014286237B2 (en) | 2013-07-03 | 2020-08-20 | F. Hoffmann-La Roche Ag | mRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist |
| US9268662B2 (en) | 2013-08-01 | 2016-02-23 | Oracle International Corporation | Method and system for a high availability framework |
| US20160022720A1 (en) | 2013-08-02 | 2016-01-28 | Children's Hospital Medical Center | Compositions and methods for treating disease states associated with activated t cells and/or b cells |
| US20160115556A1 (en) | 2013-10-19 | 2016-04-28 | Trovagene, Inc. | Detecting mutations in disease over time |
| KR102473485B1 (en) | 2013-11-11 | 2022-12-01 | 암젠 인크 | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers |
| DK3077004T3 (en) | 2013-12-05 | 2020-04-27 | Hoffmann La Roche | Hitherto unknown combination treatment of acute myeloid leukemia (AML) |
| AU2014372166B2 (en) | 2013-12-23 | 2017-10-26 | Novartis Ag | Pharmaceutical combinations |
| EP3094746A1 (en) | 2014-01-14 | 2016-11-23 | Daiichi Sankyo Company, Limited | Gene signatures associated with sensitivity to mdm2 inhibitors |
| US20170037086A1 (en) | 2014-04-09 | 2017-02-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles with pth activity |
| WO2015179799A1 (en) | 2014-05-22 | 2015-11-26 | The General Hospital Corporation | DD1alpha RECEPTOR AND USES THEREOF IN IMMUNE DISORDERS |
| TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
| EP3659621A1 (en) | 2014-09-13 | 2020-06-03 | Novartis AG | Combination therapies for cancer |
| BR112017005736A2 (en) | 2014-09-24 | 2017-12-12 | Aileron Therapeutics Inc | peptidomimetic macrocycles and formulations thereof |
| CA2961258A1 (en) | 2014-09-24 | 2016-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| WO2016056673A1 (en) | 2014-10-09 | 2016-04-14 | Daiichi Sankyo Company, Limited | Algorithms for gene signature-based predictor of sensitivity to mdm2 inhibitors |
| WO2016055497A1 (en) | 2014-10-10 | 2016-04-14 | F. Hoffmann-La Roche Ag | Methods for personalizing patient cancer therapy with an mdm2 antagonist |
| WO2016073184A1 (en) | 2014-11-04 | 2016-05-12 | Dana Farber Cancer Institute, Inc. | Compositions and methods for treating multiple myeloma |
| EP3237638B1 (en) | 2014-12-24 | 2020-01-15 | F.Hoffmann-La Roche Ag | Therapeutic, diagnostic and prognostic methods for cancer of the bladder |
| MX2017011834A (en) | 2015-03-20 | 2018-04-11 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof. |
| WO2017004548A1 (en) | 2015-07-01 | 2017-01-05 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| MX2017016251A (en) | 2015-07-02 | 2018-04-20 | Dana Farber Cancer Inst Inc | Stabilized anti-microbial peptides. |
| WO2017023933A2 (en) | 2015-08-03 | 2017-02-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| MX2018002723A (en) | 2015-09-03 | 2018-08-15 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof. |
| CN108368161A (en) | 2015-09-10 | 2018-08-03 | 艾瑞朗医疗公司 | Peptidomimetic macrocyclic compound as MCL-1 conditioning agents |
| KR20180128022A (en) | 2016-03-21 | 2018-11-30 | 에일러론 테라퓨틱스 인코포레이티드 | A companion diagnostic tool for peptidomimetic giant rings |
| WO2017205786A1 (en) | 2016-05-27 | 2017-11-30 | Aileron Therapeutics, Inc. | Cell permeable peptidomimetic macrocycles |
| WO2017218949A2 (en) | 2016-06-17 | 2017-12-21 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| WO2018165575A2 (en) | 2017-03-09 | 2018-09-13 | Aileron Therapeutics, Inc. | Warhead-containing peptidomimetic macrocycles as modulators of bfl-1 |